

Press release

# **XCounter issue new shares to invite new shareholders**

To increase the number of shareholders in the company and create conditions for an improved liquidity in the share, XCounter has decided to issue new shares in cooperation with Mangold Fondkommission and Avanza Bank by targeting the general public in Sweden with a maximum issue of 400,000 new shares in the company. Subscription period is open from 11 to 27 June 2012.

The subscription price in the offer is SEK 24.65 per share which corresponds to a discount of seven (7) per cent against the last price paid for the XCounter share. The total offer will not exceed a gross value of EUR 1m.

The Board of Directors made their decision to issue new shares based on the authorization they received at the Annual General Meeting 26 April 2012. The Board of Directors assess the offered price to be at market value and consider in total the offer, as to be able to fulfill the above stated purposes, that is made without preferential rights of the shareholders, to contribute to create value for all of the Company's shareholders.

"After the relisting to NASDAQ OMX First North from AIM London it feels very good that we now are able to invite new shareholders to the company that together with current shareholder get the opportunity to take part of the further development of the Group", says CEO Fredrik Henckel in a comment to the offer.

The offer is conditioned that no circumstances occur that according to the Board of Directors would mean that it's not in the Company or the shareholders interest to fulfill the offer. The total offer will, as described above, not exceed EUR 1m and is by that not resulting in the obligation to establish a prospectus.

### Information meetings for the issue of new shares

In relation to the offer XCounter arrange a number of investor meetings where the CEO Fredrik Henckel will make a presentation of the Company and where the general public gets the opportunity to get a closer review of XCounter.

- Lunch for investors with Financial Hearings at Operaterassen in Stockholm 13 June 2012 at 12:00 a clock
- Lunch for investors at Elite Hotel Savoy in Malmoe 15 June 2102 at 12:00 a clock
- Lunch for investors at Radisson Blu Scandinavia Hotel in Gothenburg 18 June 2012 at 12:00 a clock

Anyone interested to participate at any of the above occasions is requested to contact Mangold Fondkommission via telephone +46 8 503 015 50 or via email <u>info@mangold.se</u> at the latest two days before respective lunch.

### **Documents in relation to the offer**

Teaser, appendix for terms, subscription form and other relevant documents are available at the Company's website and Mangold's website. For further information please follow the link below.

http://www.mangold.se/MangoldOnline/CurrentOffersNews.aspx?newsId=322&index=1

## **Financial adviser**

Mangold Fondkommission is financial adviser to XCounter for this offer.

## For further information

Jean-Philippe Flament, Chairman of the Board for XCounter AB, +33 680 869 787 Fredrik Henckel, CEO for XCounter AB, +46 760 198 402

## **XCounter AB in summary**

XCounter AB is a technology leader in direct conversion and photon counting digital X-ray imaging for medical, dental and industrial markets targeting to be the leading provider of high-end X-ray sensors. The Company's share is traded at the stock exchange Nasdaq OMX First North. Mangold Fondkommission AB, telephone +46 8 503 015 50, is the Company's Certified Adviser and Liquidity Provider. Further information about XCounter AB can be found at <u>www.xcounter.se</u>.

## Important information

This press release is not considered to be an offer of any securities in XCounter AB, neither in US nor elsewhere, and no securities will be offered outside Sweden. This press release is not allowed to be distributed, direct or indirect, in or to US, Canada, Japan or Australia or elsewhere outside Sweden. The shares that is mentioned in this press release is not registered and will not be registered according to United States Securities Act 1933 ("Securities Act"), and is not allowed to be offered or sold in US.